Bajaj Healthcare Reports ₹22.85 Crore Quarterly Loss, Annual Profit Drops 60% on One-Offs

Bajaj Healthcare Ltd. reported a net loss of ₹22.85 crore for the fourth quarter ended March 31, 2026. This contrasts with profits in the same period last year. For the full fiscal year FY26, net profit after tax fell 60.08% to ₹15.77 crore.

Annual revenue, however, grew 9.99% to ₹618.17 crore, while quarterly revenue declined 7.16% year-on-year to ₹156.01 crore.

The significant drop in annual profit was primarily due to a substantial ₹33.25 crore exceptional loss from the reversal of technical know-how income. Additionally, losses from discontinued operations contributed ₹5.54 crore to the annual figures.

Current borrowings increased to ₹185.90 crore from ₹157.96 crore in the prior year. Long-term debt decreased from ₹64.67 crore to ₹47.57 crore.

The statutory auditors issued an unmodified opinion on the company's financial statements, and the board recommended a dividend of ₹1.50 per share.

Impact of One-Offs

Bajaj Healthcare's reported earnings were heavily impacted by non-recurring events, making it challenging to assess the underlying operational performance. The rise in short-term debt also requires careful management to ensure liquidity and control finance costs.

Despite the quarterly loss, the recommended dividend payout signals some confidence from the board in the company's future prospects.

Company Overview

Bajaj Healthcare operates in the pharmaceutical sector, focusing on Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company serves both domestic and export markets and has been expanding its manufacturing capabilities, particularly in API production, to capitalize on global pharmaceutical supply chain opportunities.

Investor Focus Ahead

Shareholders will now focus on evaluating the core business's strength and sustainability, looking past the exceptional items. Managing working capital and short-term debt efficiently will be key.

Future profitability hinges on stable revenue streams, effective cost control, and avoiding significant one-off charges. The recommended dividend offers shareholders an immediate return.

Key Risks

Investors should monitor potential margin pressure from industry competition and volatile raw material prices. There is also a risk of further write-downs or losses from discontinued operations. Effectively managing increased short-term debt obligations and their associated finance costs will be crucial.

Industry Peers

• Divi's Laboratories: A dominant API player known for strong margins and consistent growth, though subject to API market cycles.
• Laurus Labs: Active in APIs and formulations, facing similar API segment volatility.
• Aarti Drugs: Primarily an API manufacturer, performance is sensitive to product mix and raw material prices.

What to Watch Next

Key areas for investors to track include management commentary on the drivers behind the income reversal and discontinued operations. Earnings calls will be important for understanding the outlook for key product segments. Trends in short-term borrowing and working capital management are also critical. Investors will look for updates on capacity utilization, new product pipelines, the performance of discontinued operations, and the company's future dividend policy.